Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314183 | 0.77 | LMNA (0.53) | PRSS1ACRKMT2ACYP3A4MAPT | |
| Aziridine SCHEMBL5185484 | 0.77 | ALDH1A1 (0.50) | MAPTKDM4ELMNAHTTCYP2D6 | |
| 1,4-Dichlorobenzene SCHEMBL29046429 | 0.77 | LMNA (0.53) | PRSS1ACRKMT2ACYP3A4MAPT | |
| Piperazine SCHEMBL7635861 | 0.75 | ALDH1A1 (0.49) | MAPTKDM4ELMNAHTTCYP2D6 | |
| Piperazine SCHEMBL5875357 | 0.75 | ALDH1A1 (0.49) | MAPTKDM4ELMNAHTTCYP2D6 | |
| SCHEMBL16651220 | 0.75 | PROKR1 (0.47) | PROKR1PRSS1ACRKMT2ACYP3A4 | |
| SCHEMBL3739461 | 0.74 | MAPT (0.44) | MAPTKDM4ELMNAHTTCYP2D6 | |
| SCHEMBL15536798 | 0.74 | BCHE (0.44) | KMT2ACYP3A4MAPTLMNAHTT | |
| SCHEMBL15006564 | 0.73 | LMNA (0.42) | MAPTKDM4ELMNAHTTCYP2D6 | |
| Pyrrolidine SCHEMBL2531422 | 0.72 | ALDH1A1 (0.46) | KMT2AMAPTKDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-09 | — | — | US | disclosed |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10335402-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-10308635-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-21 | — | — | US | disclosed |
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-01 | — | — | US | disclosed |
| EP-3218363-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2017-09-20 | — | — | EP | disclosed |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| WO-2016075457-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2016-05-19 | — | — | WO | disclosed |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3010900-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2855449-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2014202999-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2014-12-24 | — | — | WO | disclosed |
| WO-2013179024-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | OPRM1 665/4885PROKR1 1/4885PRSS1 1289/4885 |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | OPRM1 589/4885PROKR1 1/4885PRSS1 1220/4885 |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | GIPR, PROKR1, PROKR2 | OPRM1 49/4885PROKR1 2/4885PRSS1 919/4885 |
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | OPRM1 589/4885PROKR1 1/4885PRSS1 1220/4885 |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | OPRM1 665/4885PROKR1 1/4885PRSS1 1289/4885 |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | OPRM1 665/4885PROKR1 1/4885PRSS1 1289/4885 |
| US-10308635-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | GIPR, PROKR1, PROKR2 | OPRM1 49/4885PROKR1 2/4885PRSS1 919/4885 |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | OPRM1 665/4885PROKR1 1/4885PRSS1 1289/4885 |
| US-10335402-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | PROKR1, PROKR2, GIPR | OPRM1 117/4885PROKR1 1/4885PRSS1 498/4885 |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | OPRM1 665/4885PROKR1 1/4885PRSS1 1289/4885 |
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | GIPR, PROKR1, PROKR2 | OPRM1 49/4885PROKR1 2/4885PRSS1 919/4885 |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | OPRM1 665/4885PROKR1 1/4885PRSS1 1289/4885 |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PGC | OPRM1 37/4885PROKR1 1/4885PRSS1 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.